9th CAR-TCR Summit

The commercial success of cell therapies is continuing to grow! With a recent TIL approval, a shift to earlier line CAR-T treatment, and further approvals set for this year, 2024 will be pivotal to demonstrate the clinical benefit of cell therapies and advance breakthroughs in solid tumors and autoimmunity.

That's why now's the time to join the 9th CAR-TCR Summit: the industry's definitive forum committed to progressing end-to-end cell therapy development. This year's 2-day conference will accommodate in-depth tracks covering Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, Analytical Development and Supply Chain and Clinical Operations.

This is your team's one-stop shop for all functions to discover cutting-edge innovations, significant clinical data and gain insights into how to conquer the bottlenecks withholding optimal durability, accessibility, safety and cost-efficiency.

Join 130+ expert speakers and 1,000+ cell therapy experts to collaborate to achieve the shared goal of delivering these curative treatments to the ever-growing population of patients in need.

URLs:
Website: https://go.evvnt.com/2431289-0?pid=176 
Tickets: https://go.evvnt.com/2431289-2?pid=176 
Brochure: https://go.evvnt.com/2431289-3?pid=176

Time: 8:00 AM - 5:00 PM

Prices:
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + Bonus Day - Drug Developer Pricing: USD 4197.00,
Full Access Pass - Drug Developer Pricing: USD 5395.00,
Conference Only - Discounted Pricing: USD 2599.00,
Conference + Bonus Day - Discounted Pricing: USD 3597.00,
Full Access Pass - Discounted Pricing: USD 4595.00,
Conference Only - Vendor Pricing: USD 5179.00,
Conference + Bonus Day - Vendor Pricing: USD 6397.00,
Full Access Pass - Vendor Pricing: USD 7615.00

Speakers: Carl June, Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, University of Pennsylvania, Nelly Viseux, Senior Vice President, Process and Analytical Development and Clinical Manufacturing, 2SeventyBio, Christian Aguilera, Sandoval Associate Director of Scientific Affairs, Accellix, An Ouyang, Product Manager, ACRO Biosystems, Cintia Piccina, Chief Commercial Officer, Adaptimmune, Mark Stielow, Vice President, Manufacturing and Technical Operations, Adaptimmune, John Lunger, Chief Patient Supply Officer, Adaptimmune, Ekatherina Goryachikov, Vice President and Head of Clinical Operations, Adicet Bio, Gary Shapiro, Vice President, Discovery Biology, Affini-T Therapeutics, Damien Hallet, Vice President, CMC, Affini-T Therapeutics, Patrick Halvey, Director Clinical Biomarker Development, Precision and Translational Medicine, Affini-T Therapeutics, Yama Abassi, Associate Vice President, Agilent, Cecile Bauche, Chief Scientific Officer, Alaya.bio, Renaud Vaillant, Founder and President, Alaya.bio, Yuki Kato, Mave Associate Director, Product Management, AllCells, Luke Pase, Chief Technology Officer, Anocca, Reagan Jarvis, Co-Founder and Chief Executive Officer, Anocca, Qi Wei, Senior Vice President, Head of Technical Operations, Appia Bio, Patrick Rivers, Managing Director and Head of Research, Aquilo Capital Management, Haixia Wang, Head of Analytical Development, Arsenal Bio, Christopher Murriel, Vice President, PreClinical Pharmacology, Arsenal Bio, Samuel Williams, Vice President, Early Product Development, Arsenal Bio, Natalia Ulyanova, Director, Business Development, Oncology, Astellas Pharma, Y. Morris Chen, Cell and Gene Therapy Lead, Research and Development IT, AstraZeneca, Pascal Touchon, President and Chief Executive Officer, Atara Biotherapeutics, Jordan Rumbelow, Account Manager, Beacon Targeted Therapies, Rachel East, Research Analyst, Beacon Targeted Therapies, Felix Montero, Global Senior Scientific Director, bioMerieux, Bassem Gayed, Senior Technical Director, CAR-T Process Engineering, MSAT, Bristol Myers Squibb, Arun Pores Fernando, Director, Business Development, Search and Evaluation, Cell Therapy, Bristol Myers Squibb, Chien-Chung Chen, Director, Analytical Development, Cabaletta Bio, Jenell Volkov, Senior Director and Head, Translational Medicine, Cabaletta Bio, Gwen Binder, President, Science and Technology, Cabaletta Bio, Samik Basu, Chief Scientific Officer, Cabaletta Bio, Francesca Barone, Chief Scientific Officer, Candel Therapeutics, Adrian Bot, Chief Scientific Officer, Executive Vice President, Research and Development, Capstan Therapeutics, Haig Aghajanian, Head of Research and Scientific Co-Founder, Capstan Therapeutics, Justin Skoble, Vice President, Technical Operations, Caribou Biosciences, Raffaele Baffa, Chief Medical Officer, CARsgen Therapeutics, Chris Jewell, Chief Scientific Officer, Cartesian Therapeutics, Milos Miljkovic, Chief Medical Officer, Cartesian Therapeutics, David Sourdive, Co-Founder and Executive Vice President, CMC and Manufacturing, Cellectis, Amrik Singh, Senior Fellow, Immunology Product Design and Strategy, Cell Signaling Technology, Eytan Breman, Head, Research and Development, Celyad Oncology, Keith Wilson, Director, Manufacturing Science and Technology, Century Therapeutics, Matthew Hewitt, Vice President, Technical Officer CGT and Biologics, Charles River Laboratories, Gemma Moiset, Senior Group Leader, Biotherapeutics Drug Discovery, Charles River Laboratories, Stephan Grupp, Section Chief of the Cellular Therapy and Transplant Section, Children’s Hospital of Philadelphia, Simon Bornschein, Chief Executive Officer, coding.bio, Alexandria Cogdill, Executive Director and Head of Global Research and Technology Seach and Evaluation, External Innovation and Global Business Development, Daiichi Sankyo, Amy Emmert, Executive Director, Cell Therapy Facility Dana Farber, Cancer Institute, Sara Mills, Head of Cell Therapy CMC, Dark Horse Consulting, Erika von Euw, Vice President, Discovery and Translational Research, Deverra Therapeutics, Michelle Andraza Director, Global Quality Assurance and CMC, EXUMA Biotechnology, Sid Kerkar, Vice President, Research and Development, EXUMA Biotechnology, Cassandra Moran, Division of Clinical Evaluation Hematology, Center for Biologics Evaluation and Research, FDA, Oscar Onyema, Independent Expert, Formerly at Precigen, John Yu, Independent Expert, Formerly at Sana Biotechnology, Howard Wu, Co-Founder and Chief Scientific Officer, Full Circles Therapeutics, Andrew Applebury, Associate Director, Process Engineering, Fujifilm Diosnyth Biotechnologies, Sareina Wu, Chief Scientific Officer, GenomeFrontier Therapeutics, LJ Shen, Senior Vice President, Head of Research and Development, Gracell Biotechnologies, Mojca Skoberne, Entrepreneur in Residence, GV, Marcela Maus, Associate Professor of Medicine, Harvard Medical School, Director, Cellular Immunotherapy Program, Mass General Cancer Center, Karen Moniz, Technical Director, ICCBBA, Greg Deener, Chief Executive Officer, iCell Gene Therapeutics, Mamta Kalra, Senior Director, CMC, Process and Analytical Development, Immatics, Ali Mohamed, Senior Vice President, CMC, Immatics, Delfi Krishna, Vice President, Technical, Immatics, Dan Macleod, Senior Vice President, Discovery, ImmunoScape, Matthias Scroff, Chief Executive Officer, Inceptor Bio, Mark Dudley, Chief Scientific Officer, Instil Bio, Phil Johnson, President and Chief Executive Officer, Interius Biotherapeutics, Peter Prieto, Senior Vice President, Medical Affairs, Iovance Biotherapeutics, Ramona Repaczki-Jones, Executive Director, Treatment Center Operations, Cell Therapy, Iovance Biotherapeutics, George Todorov, Senior Engineer, Process, IPS, Vicki Plaks, Global Head of Cell Therapy, Translational Research, Johnson and Johnson , Andrew Snowden, Senior Director, Allogeneic and Autologous Cell Therapy Development, Johnson and Johnson, Sean Evans, Senior Associate, Venture Investments, Johnson and Johnson Innovative Medicine, Gadi Bornstein, Senior Director, External Innovation, Discovery, Product Development and Supply, Johnson and Johnson Innovative Medicine, Cameron Gardner, Director, Research and Development, JURA Bio, Elizabeth Wood, Founder and Chief Executive Officer, JURA Bio, Ying Li, Director, Early Commercial Strategy, Kite Pharma, Efe Egharevba, Executive Director, Product Team Lead, Kite Pharma, Micah Benson, Senior Vice President and Head of Research, KSQ Therapeautics, Mythili Koneru, Chief Medical Officer, Legend Biotech, Steve Gavel, Senior Vice President, Commercial Development, Legend Biotech, Joseph Maguire, Head of GMP Automation and Data, Lyell Immunopharma, Sarah Hein, Co-Founder and Chief Executive Officer, March Biosciences, Theodoros Giavridis, Associate Director, Cell Therapy, Mnemo Therapeutics, Bruce Dezube, Chief Medical Officer, Mustang Bio, Maurits Geerlings, President and Chief Executive Officer, NanoCell Therapeutics, Melissa van Pel, Head of Cell Therapy, NecstGen, Henri Bayle, Chief Technology and Development Officer, Co-Founder, NKILT Therapeutics, Raphael Ognar, President and Chief Executive Officer, Co-Founder, NKILT Therapeutics, Steve Liapis, Director, Northpond Ventures, Jie Zhang, Vice President, Head of Cell and Gene Global Value and Access, Novartis, Parameswaran Hari, Chief Development Officer, Obsidian Therapeutics, Neil Blackburn, Senior Director, Process Development and Analytic, OmniaBio, Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics